Servier to acquire Day One Biopharmaceuticals for $21.50/share in all-cash deal valued at ~$2.5B

Day One Biopharmaceuticals, Inc.

Acquisition at $21.50/share cash, total equity value ~$2.5B; premium of ~68% over March 5 close.
Day One board recommends tender; transaction expected to close in Q2 2026.
Conditions: majority of shares tendered, HSR clearance; no financing condition.
Termination fee of $87.7M payable by Day One if it accepts a superior proposal.
Servier to fund the acquisition from existing cash and investments.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Day One Biopharmaceuticals, Inc. entered into Agreement and Plan of Merger with Servier Pharmaceuticals LLC, Servier Detroit Inc., and Servier S.A.S. (effective 2026-03-06).

Action: entry
Agreement: merger
Counterparty: Servier Pharmaceuticals LLC, Servier Detroit Inc., and Servier S.A.S.
Effective: 2026-03-06

Exact text from the filing

On March 6, 2026, Servier Pharmaceuticals LLC, a Delaware limited liability company (“ Parent ”), Servier Detroit Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“ Merger Sub ”), Day One Biopharmaceuticals, Inc., a Delaware corporation (the “ Company ”), and Servier S.A.S., a French société par actions simplifiée , solely as a guarantor (“ Guarantor ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”).

View on SEC.gov

336 material agreements filed in the last 30 days. Browse all material agreements →

Source: SEC EDGAR

accession 0001193125-26-095174

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.